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Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I)
inhibition in vivo does not alter cardiac long-chain fatty acid uptake
and oxidation rates
Joost J. F. P. LUIKEN*1, Hanneke E. C. NIESSEN*, Susan L. M. COORT*, Nicole HOEBERS*, Will A. COUMANS*,
Robert W. SCHWENK*, Arend BONEN† and Jan F. C. GLATZ*
*Department of Molecular Genetics, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6200 MD Maastricht, The Netherlands, and
†Department of Human Health and Nutritional Sciences, University of Guelph, 50 Stone Road East, Guelph, Ontario, Canada N1G 2W1
Although CPT-I (carnitine palmitoyltransferase-I) is generally
regarded to present a major rate-controlling site in mitochondrial
β-oxidation, it is incompletely understood whether CPT-I is rate-
limiting in the overall LCFA (long-chain fatty acid) flux in the
heart. Another important site of regulation of the LCFA flux in
the heart is trans-sarcolemmal LCFA transport facilitated by CD36
and FABPpm (plasma membrane fatty acid-binding protein).
Therefore, we explored to what extent a chronic pharmacological
blockade of the LCFA flux at the level of mitochondrial entry of
LCFA-CoA would affect sarcolemmal LCFA uptake. Rats were
injected daily with saline or etomoxir, a specific CPT-I inhibitor,
for 8 days at 20 mg/kg of body mass. Etomoxir-treated rats
displayed a 44% reduced cardiac CPT-I activity. Sarcolemmal
contents of CD36 and FABPpm, as well as the LCFA transport
capacity, were not altered in the hearts of etomoxir-treated versus
control rats. Furthermore, rates of LCFA uptake and oxidation,
and glucose uptake by cardiac myocytes from etomoxir-treated
rats were not different from control rats, neither under basal
nor under acutely induced maximal metabolic demands. Finally,
hearts from etomoxir-treated rats did not display triacylglycerol
accumulation. Therefore CPT-I appears not to present a major
rate-controlling site in total cardiac LCFA flux. It is likely that
sarcolemmal LCFA entry rather than mitochondrial LCFA-CoA
entry is a promising target for normalizing LCFA flux in cardiac
metabolic diseases.
Key words: CD36, carnitine palmitoyltransferase-I, long-chain
fatty acid uptake, long-chain fatty acid oxidation, mitochondria,
sarcolemmal transport.
INTRODUCTION
LCFAs (long-chain fatty acids) are the major energy source
for the heart to sustain contractile activity. Since the heart can
store or synthesize LCFAs only in limited amounts, it strongly
relies on a continuous LCFA supply from the circulation [1].
LCFAs are taken up mainly via a protein-mediated mechanism,
involving two sarcolemmal LCFA-binding proteins, FABPpm
[plasma membrane FABP (fatty acid-binding protein)] and CD36
[2]. Kinetic evidence suggests that FABPpm and CD36 operate
in concert with each other, so as to make up two components of
one functional LCFA transport system. Accordingly, both proteins
were found to physically interact, based on co-immunoprecipita-
tion experiments using cardiac sarcolemmal preparations [3].
Moreover, these proteins not only facilitate LCFA uptake, but they
also regulate this process via their translocation from intracellular
stores to the sarcolemma. Notably, an increase in contractile
activity, which increases the metabolic demands of the heart, also
causes the translocation of both FABPpm and CD36 to the cell
surface to increase LCFA uptake [4].
Immediately after their trans-sarcolemmal transport, LCFAs
bind to FABPc (cytoplasmic FABP), which channels them to the
mitochondria, where LCFAs are activated by FACS (fatty acyl-
CoA synthetase), located at the cytoplasmic side of the outer
mitochondrial membrane [1,5]. In the contracting heart, the bulk
of LCFA-CoA esters is taken up into the mitochondria via CPT-I
(carnitine palmitoyltransferase-I), and subsequently degraded in
the β-oxidation pathway [1]. The portion of the LCFA-CoA esters
that is not used for mitochondrial β-oxidation is mainly esterified
into triacylglycerols for storage.
CPT-I is located within the mitochondrial outer membrane, and
converts LCFA-CoA into LCFA-carnitine. CPT-I exists in two iso-
forms, a L (liver) variant and a M (muscle) variant [6]. Both
isoforms are expressed in cardiac myocytes, but M-CPT-I is the
predominant isoform, and contributes 98% of total cardiac CPT-
I activity [7]. CPT-I provides a major site of acute regulation
of β-oxidation via its physiological inhibitor malonyl-CoA, and
its enzymatic activity towards LCFA-CoA is generally proposed
to be the overall rate-limiting step in long-term cellular LCFA
utilization [6].
However, indirect observations based on measurements of in-
tracellular malonyl-CoA levels have questioned the role of CPT-I
in the regulation of mitochondrial β-oxidation [5]. Notably, the
concentration of malonyl-CoA in the heart was estimated to
be 1–10 μM [8,9], which greatly exceeds the IC50 of M-CPT-I
for malonyl-CoA (0.02 μM; [5]). Hence, β-oxidation would be
theoretically permanently blocked if CPT-I was rate-limiting for
β-oxidation. More recently, it was observed in perfused hearts
from db/db mice that LCFA oxidation was 4-fold increased,
independent of changes in CPT-I activity [10]. These observations
suggest that CPT-I activity may not be rate-limiting for cardiac
β-oxidation.
Abbreviations used: ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; CPT-I, carnitine palmitoyltransferase-I; ECL, enhanced
chemiluminescence; FABPc, cytoplasmic fatty acid-binding protein; FABPpm, plasma membrane fatty acid-binding protein; FATP, fatty-acid transport
protein; LCFA, long-chain fatty acid; L-CPT-I, liver CPT-I; M-CPT-I, muscle CPT-I; OXPHOS, oxidative phosphorylation; PPARα, peroxisome-proliferator-
activated receptor α.
1 To whom correspondence should be addressed (email j.luiken@gen.unimaas.nl).
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Another site regulating LCFA oxidation appears to be at
the level of the sarcolemma, where LCFA uptake into cardiac
myocytes is mediated by the FABPpm/CD36 transport system
[2,4]. Namely, CD36-mediated LCFA uptake is closely co-
ordinated with subsequent metabolism. This is illustrated by the
observation that during the initial LCFA uptake phase, which
is considered to be independent of metabolism, the bulk of
LCFA is rapidly metabolized [11]. Furthermore, in CD36-null
mice, in which CPT-I protein expression is not altered, LCFA
oxidation is impaired, particularly during a metabolic challenge
[12]. Finally, in db/db mice, markedly increased rates of cardiac
LCFA oxidation were solely attributable to an elevated content of
sarcolemmal CD36, whereas CPT-I activity was unaltered [10].
Taken together, a number of observations in recent years
have raised the question whether cardiac LCFA fluxes are only
regulated by CPT-I or predominantly by CPT-I in combination
with other regulatory mechanisms. Therefore, we sought to
partially block CPT-I in the heart by the chronic administration of
etomoxir to rats, as has been done previously [13–16]. Thereafter,
we measured cardiac triacylglycerol content, LCFA transport and
transporters in giant sarcolemmal vesicles and, finally, LCFA
uptake and oxidation by cardiac myocytes. We find that in eto-
moxir-treated rats, despite a marked reduction (∼50%) in CPT-I
activity, the FABPpm-CD36-mediated LCFA uptake is not
altered, and LCFA oxidation rates are maintained during both
basal and maximal metabolic demands. Therefore, we conclude
that under these circumstances CPT-I does not appear to be rate-
limiting in regulating cardiac LCFA fluxes.
EXPERIMENTAL
Materials
[1-14C]Palmitic acid and [3H]glucose were obtained from
Amersham Life Science (Little Chalfont, U.K.). BSA (fraction V),
collagenase type VII and oligomycin were purchased from
Sigma (Saint Louis, MO, U.S.A.). Collagenase type II was
from Worthington (Freehold, NJ, U.S.A.). Non-fat dried skimmed
milk powder (Marvel) was obtained from Premier Brands (More-
ton, U.K.). Western blot reagents were from Bio-Rad Laboratories
(Hercules, CA, U.S.A.) and the ECL® (enhanced chemilumines-
cence) kit was from Amersham Pharmacia Biotech (Buckingham,
U.K.). CD36 was detected with a monoclonal antibody (MO25)
directed against human CD36, provided by Dr N. Tandon (Otsuka
Pharmaceuticals, Bethesda, MD, U.S.A.). A rabbit polyclonal
antibody against rat hepatic membrane fatty acid binding protein
was used to detect FABPpm (gift from Dr D. Sorrentino, Mount
Sinai Medical Center, New York City, NY, U.S.A.). M-CPT-
1 antibodies were a gift from Dr G. Woldegiorgis (Oregon
Graduate Institute of Science and Technology, Beaverton, OR,
U.S.A.). An antibody directed against Ser79-phosphorylated ACC
(acetyl-CoA carboxylase) was from Upstate (Dundee, U.K.).
Mitochondrial OXPHOS (oxidative phosphorylation) complexes
were detected using a monoclonal antibody kit from MitoSciences
(Eugene, OR, U.S.A.). Rabbit anti-mouse immunoglobulin horse-
radish peroxidase and pig anti-rabbit immunoglobulin horseradish
peroxidase were obtained from DAKO (Glostrup, Denmark).
Etomoxir was purchased from Dr H.P.O. Wolf (Projekt
Entwicklung GmbH, Allensbach, Germany).
Animals
Male Lewis rats, weighing 150–200 g, were used in the present
study. Animals were kept on a 12 h:12 h light/dark cycle and
fed a Purina Chow diet and water ad libitum. The rats were
divided into two groups: (1) control and (2) etomoxir. Etomoxir
(20 mg/kg of body weight) was dissolved in 0.9% (w/v) NaCl and
administered intraperitoneally for 8 days. Control rats received
saline. The last injection was given 24 h before the experiment.
Ethical approval for all experimental procedures was obtained
from the Experimental Animal Committee of the Maastricht
University, and the study conforms to the Guide for the Care
and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85–23, revised 1996).
Animals were anaesthetized with an intraperitoneal injection of a
nembutal and heparin (3:1) mixture. Subsequently, the heart was
removed for LCFA uptake studies and for analyses of transporter
protein contents.
Isolation of giant sarcolemmal vesicles for determination
of palmitate transport and transporters
Giant vesicles were prepared from heart muscle, as previously
described [2]. These vesicles are solely derived from plasma
membrane, and are virtually uncontaminated with intracellular
membranes. LCFAs do not merely loosely associate with giant
vesicles, but are taken up across the vesicle membrane. Within
the lumen of the vesicles, FABPc is abundantly present to act
as an LCFA sink [2]. These giant vesicles were used for the
assessment of the sarcolemmal content of LCFA transporters (see
below). These vesicles were also used for the measurement of the
cardiac LCFA uptake capacity, as previously described in [2].
Isolation of cardiac myocytes
Cardiac myocytes were isolated from control or etomoxir-treated
rats using a Langendorff perfusion system and a Krebs-Henseleit
bicarbonate buffer equilibrated with 95% (v/v) O2 and 5% (v/v)
CO2 (medium A) at 37 ◦C as previously described [11]. Cells were
only used for subsequent tracer uptake studies when >80% of
the cells had a rod-shaped appearance.
Palmitate utilization by cardiac myocytes
Cells (2.0 ml; 8–12 mg of wet mass/ml) were preincubated in
20 ml vials in the absence or presence of 30 μM oligomycin
for 15 min at 37 ◦C under continuous shaking. At the
start of the incubations, a mixture of [1-14C]palmitate/BSA
complex and [1-3H]deoxyglucose was added to cell suspensions
(final concentrations: 100 μM or 600 μM palmitate with
corresponding palmitate/BSA ratios of 0.33 or 2.0 respectively;
and 100 μmol/l deoxyglucose) as previously described. Uptake
of [14C]palmitate and [3H]deoxyglucose (over 3 min) was
determined by scintillation counting. Oxidation of [14C]palmitate
(20 min incubation) into CO2 via base trapping was determined
after addition of perchloric acid (0.5 M) to cell suspensions [11].
Oxygen consumption by cardiac myocytes
Incubations for measurement of oxygen consumption were
performed in a specially designed vial with a total volume of 7 ml.
Because a gas phase disturbs oxygen consumption measurements,
the incubation vial was completely filled with a cell suspension
(5–8 mg of wet mass/ml) that was saturated with 95% (v/v) O2
and 5% (v/v) CO2 immediately before capping the vial. Under
continuous shaking at 37 ◦C, oxygen consumption was measured
with a Clark-type electrode. Hence, measurements started with
a pO2 between 500 and 600 mmHg. Furthermore, measurements
were corrected for loss of oxygen due to consumption by the
Clarke electrode and to diffusion.
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Sample preparation for Western blotting and CPT-I activity
measurement
Total tissue homogenates to be used for Western blotting and for
CPT-I activity measurement were prepared from heart and,
for reference, from liver. Briefly, tissues (approx. 50 mg) were
homogenized in 1 ml of Tes buffer (10 mM Tris/HCl, 2 mM
di-Na-EDTA and 250 mM sucrose, pH 7.4) supplemented with
PMSF and DMSO for 5 interrupted 5 s bursts with an Ultra Turrax
homogenizer (IKA, Staufen, Germany) set at 24000 rev./min.
Thereafter, cells were disintegrated in 4 cycles (5 s on, 15 s off)
with an amplitude of 10–12 using an Ultrasonic Disintegrator
(Soniprep 150, Sanyo Gallenkamp Plc.). Protein concentration
was determined and samples were stored at −80 ◦C.
SDS/PAGE and Western blotting
Total tissue homogenates (20 μg) and giant vesicle preparations
(3 μg) respectively, were separated by SDS/PAGE on 12.5%
(w/v) acrylamide gels at 150 V and room temperature (21 ◦C).
Subsequently, proteins were transferred on to nitrocellulose
membranes by Western blotting and detected for CD36, FABPpm,
ACC, CPT-I and OXPHOS complexes. Western blotting for
the detection of CD36, FABPpm [2] and CPT-I [17] was
performed as described previously, and for the detection of
OXPHOS complexes according to the manufacturer’s instruction.
The protein bands were visualized using ECL, and immunoblot
intensities were analysed by using densitometry using Quantity
One software (Bio-Rad Laboratories, Hercules, CA, U.S.A.).
Assay of CPT-1 activity
CPT-I activity was assayed in total tissue homogenates by
the CPT-forward measurement. In this assay, palmitoylcarnitine
formation from palmitoyl-CoA and an ATP-regenerating system
was determined as previously described in [18].
Assay of intracellular triacylglycerol content
Upon thawing, pieces of heart and liver tissue (20 mg wet
mass) from control and etomoxir-treated rats were subjected
to lipid extraction and TLC, after which TLC plates were
sprayed with a mixture of rhodamine B-6G and fluorescein in
methanol for UV detection using a Fluor-S-MultiImager (Bio-Rad
Laboratories, Hercules, CA, U.S.A.). These methods are detailed
by Hasselbaink et al. [19]. Spots were quantified using Quantity-
One software (Bio-Rad Laboratories).
Other procedures
Blood glucose was determined by use of a Euroflash® pocket-
scan blood glucose meter (Lifescan, Milpitas, CA, U.S.A.).
Cellular wet mass was obtained from cell samples taken during
the incubation period and determined after centrifugation for 2–
3 s at maximal speed in a microcentrifuge and subsequent removal
of the supernatant. Protein was quantified with the bicinchoninic
acid protein assay (Pierce, Rockford, IL, U.S.A.) according to the
manufacturer’s instructions.
Statistics
All results are reported as means +− S.E.M. Statistical difference
between groups was tested with a Student’s t test, or the Mann–
Whitney U test for not normally distributed data. P values equal
to or less than 0.05 were considered significant.
Table 1 Characteristics of rats treated for 8 days with 20 mg/kg etomoxir
Results are means +− S.E.M., ∗P < 0.05, etomoxir-treated rats (n = 6) versus control rats
(n = 6).
Parameter Control Etomoxir
Body massbegin (g) 227 +− 9 228 +− 10
Body massend (g) 256 +− 9 253 +− 9
 Body mass (g) 29 +− 3 25 +− 4
Heart mass (g) 0.79 +− 0.02 0.88 +− 0.03∗
Heart mass/body mass (×103) 3.70 +− 0.20 4.10 +− 0.20
Liver mass (g) 10.6 +− 0.3 11.9 +− 0.4∗
Liver mass/body mass (×103) 41.3 +− 1.1 46.9 +− 1.5∗
Hindlimb mass (g) 1.50 +− 0.05 1.50 +− 0.03
Hindlimb mass/body mass (×103) 5.87 +− 0.02 5.94 +− 0.11
Plasma glucose (mmol/l) 7.50 +− 0.23 7.76 +− 0.37
RESULTS
Characteristics of etomoxir-treated rats
The treatment of Lewis rats for 8 days with 20 mg/kg etomoxir did
not alter blood glucose, which is in line with comparable etomoxir-
feeding studies [13,15,16]. Similarly, etomoxir feeding did not
affect general growth characteristics such as gain in body mass,
nor did it affect hindlimb muscle mass (Table 1). However, heart
mass and liver mass were both significantly increased by 11%
in etomoxir-treated rats. Such cardiac and hepatic hypertrophy
has previously been described in other etomoxir-feeding studies
(e.g. see [13,14,20]), and provides confirmation that the present
etomoxir treatment was effective.
Effects of etomoxir on cardiac and hepatic CPT-I activity/expression
and triacylglycerol contents
As expected, chronic administration of etomoxir induced
decreases in CPT-1 activity in heart (−44%) and liver (−56%;
Figure 1A). Remarkably, the expression of the M-CPT-I protein
in the heart was increased by 1.7-fold (Figure 2A), which
could possibly reflect a compensatory mechanism. In contrast,
expression levels of the OXPHOS complexes I, II and V were
unchanged between hearts of control and etomoxir-treated rats,
indicating that the etomoxir-induced up-regulation of CPT-I
expression was not accompanied by an overall increase in
mitochondrial protein content (Figure 2B).
Administration of etomoxir to rodents is known to have marked
effects on body lipid stores (e.g. see [14,20]). With respect
to cardiac lipid pools, we examined only the intramyocellular
triacylglycerol content, because this is the major intracellular
depot of LCFA [11]. The intramyocellular triacylglycerol content
was not altered in etomoxir-treated rats (Figure 1B). In contrast,
in liver there was a 2.1-fold increase in triacylglycerol content
(Figure 1B).
Effects of etomoxir on cardiac LCFA transport and transporters
The protein expressions of both FABPpm and CD36 were not
altered by etomoxir-treatment (Figure 3B). Since it is not the total
tissue expression of these transporters that determines the rate
of LCFA uptake but rather their localization at the cell surface,
giant sarcolemmal vesicles were prepared from cardiac tissue
to study the presence of these transporters at the sarcolemma.
In previous studies we have shown that these giant vesicles are
purely derived from myocytic sarcolemma [2]. In agreement, the
muscle-specific caveolin isoform, caveolin-3, was found to be
enriched in giant vesicles compared with total tissue homogenates,
whereas CPT-I was not detectable, indicating that there is no
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Figure 1 Effects of in vivo etomoxir treatement on CPT-I activity and triacylglycerol content in heart and liver
(A) CPT-I activity was measured in tissue homogenates, and (B) triacylglycerol content was measured in pieces of tissue as described in the Experimental section. Results are means +− S.E.M. for
experiments carried out with tissue preparations from four control rats (C) and four etomoxir-treated rats (Eto). ∗Significantly different from control (P < 0.05).
Figure 2 Effect of in vivo etomoxir treatment on expression of M-CPT-I and OXPHOS complexes in the heart
Contents of (A) M-CPT-I and (B) OXPHOS complexes were measured in heart homogenates using Western blotting. (A) The Western blot left of the graph demonstrates that the used antibody (a gift
from Professor V. Zammit, Hannah Research Institute, Scotland, U.K.) is specific against M-CPT-I. Namely, an 88 kDa signal was detected in the heart, corresponding to the reported molecular mass
of M-CPT-I [6], whereas such a signal was undetectable in liver, which expresses only L-CPT-I. Gels were loaded with equal quantities of protein for each cell lysate (50 μg per lane). Representative
blots are shown comparing cardiac expression levels of (A) M-CPT-I, (B) OXPHOS complexes, and β-actin (loading control, detected at 45 kDa) between control and etomoxir-treated rats. Complex
I was detected at 20 kDa, complex II at 30 kDa and complex V at 60 kDa. Results are means +− S.E.M. for experiments carried out with heart homogenates from six rats in each group. C, control rats;
Eto, etomoxir-treated rats. ∗Significantly different from control (P < 0.05).
contamination of mitochondria (Figure 3A), and also not of
other subcellular organelles [21]. In line with their total tissue
expression, sarcolemmal localizations of both FABPpm and CD36
were not altered (Figure 3C).
The giant vesicles also are suitable for determining the uptake
capacity of LCFA across the sarcolemma into the heart, because:
(i) in these vesicles all transporters are fixed at the vesicle surface
(due to absence of transporter recycling processes between vesicle
lumen compartments and the surface); and (ii) LCFA transport
rates are measured independently from their metabolism [2]. The
LCFA uptake capacity into cardiac-derived giant sarcolemmal
vesicles was not altered by the etomoxir treatment (Figure 3D).
Thus, despite the chronic inhibition of CPT-I in etomoxir-treated
hearts, there were no concurrent changes in sarcolemmal LCFA
transport capacity, nor in the expression and the subcellular
localization of LCFA transporters.
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Figure 3 Effect of in vivo etomoxir treatment on expression and sarcolemmal localization of FABPpm and CD36 in the heart and on cardiac LCFA transport
capacity
(A) Characterization of giant vesicles as sarcolemmal preparation. Heart homogenates (H) and heart giant vesicles (GV) were prepared as described in the Experimental section, and used for
measurement of contents of caveolin-3 and CPT-I. (B) Heart homogenates were used for measurement of total tissue expression of FABPpm and CD36 (total protein), and giant vesicles were used
to (C) detect both transporters at the sarcolemma (sarcolemmal protein), and to (D) measure palmitate uptake. Representative Western blots are shown. Caveolin-3 was detected at 18 kDa, CPT-I at
88 kDa, FABPpm at 43 kDa, and CD36 at 88 kDa. Results are means +− S.E.M. for experiments carried out with heart homogenates or vesicle preparations from 6 rats in each group. C, control rats;
Eto, etomoxir-treated rats.
Effects of etomoxir on the dynamics of LCFA uptake and oxidation
by cardiac myocytes
Cardiac myocytes were chosen as the preferential model
to measure cardiac LCFA fluxes because the extracellular
environment can be fully controlled while both vascular factors
and the endothelial barrier are eliminated. Furthermore, the large
extracellular space in incubations of cardiac myocytes allows the
exogenous LCFA concentration to remain constant during the ini-
tial uptake period, which avoids complicated calculations and
assumptions in the case of the limited vascular space in the
perfused working heart, where the substrate becomes rapidly
depleted. However, compared to working hearts, metabolic rates
of non-contracting myocytes are lower. Thus basal oxygen
consumption amounted to 20.5 +− 2.2 μl of O2/g of wet mass
per min (n = 3), in agreement with measurements of others [22].
This is 10–15 % of the oxygen consumption by the working rat
heart (e.g. see [23]). For stimulation of metabolic rates of cardiac
myocytes, we applied the mitochondrial inhibitor oligomycin.
Oligomycin, at an optimal concentration of 30 μM, effectively
blocks the F1F0-type proton pump while not affecting the electron
transfer chain [4,24]. Oxygen consumption by oligomycin-treated
cardiac myocytes amounted to 146.6 +− 10.6 μl of O2/g of wet
mass per min (n = 3), which is 7.2-fold higher than by their
non-stimulated counterparts, and closely resembles the oxygen
consumption of the working heart of approx. 180 +− 50 μl of
O2/g of wet mass per min. Oligomycin treatment also results
in increased intracellular AMP/ATP levels, and consequently,
activation of AMPK (AMP-activated protein kinase). In its
turn, AMPK phosphorylates ACC at Ser79, resulting in an
inhibition of its enzymatic activity and a subsequent reduction
in intracellular malonyl-CoA levels. In cardiac myocytes from
both control and etomoxir-treated rats, oligomycin treatment
resulted in a similar (>5-fold in both cases) increase in ACC-Ser79
phosphorylation (Figure 4), indicating that chronic exposure of
rats to etomoxir did not affect upstream events regulating CPT-I
activity, most notably acute modulation of malonyl-CoA levels by
ACC.
We have studied the effects of oligomycin on LCFA uptake at
externally added palmitate concentrations of 100 and 600 μM,
reflecting low and high physiological concentrations of this
substrate as occurring in the cardiac interstitial space [2]. Similarly
to our observations in giant vesicles, basal LCFA uptake was not
significantly altered in cardiac myocytes from etomoxir-treated
rats, either at 100 or 600 μM palmitate (Figures 5A and 5B).
At both palmitate concentrations, addition of 30 μM oligomycin
increased LCFA uptake into cardiac myocytes from control- and
etomoxir-treated rats by ∼1.4-fold (Figures 5A and 5B).
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Figure 4 Effect of in vivo etomoxir treatment on phosphorylation of ACC in
oligomycin-stimulated cardiac myocytes
Cardiac myocytes were isolated from contol rats (C) and etomoxir-treated rats (Eto). Cardiac
myocytes were then incubated for 15 min in the absence (none) or presence of 30 μM oligomycin
(Oli). For assessment of cellular content of AMPKα2 (predominant isoform of the catalytic
α-subunit of AMPK in the heart, detected at 63 kDa and used as loading control) and of
phosphorylation of ACC at Ser79 [pACC (Ser79)], cardiac myocytes were pelleted, dissolved in
sample buffer, after which Western blots were performed with phosphospecific antibodies. Gels
were loaded with equal quantities of protein for each cell lysate (50 μg per lane). A representative
Western blot is presented out of three experiments.
Likewise, the basal LCFA oxidation rates did not differ
between cardiac myocytes from control and etomoxir-treated rats
(Figures 5C and 5D). In the presence of oligomycin, palmitate
oxidation was similarly stimulated to the same extent (∼6.8-fold)
in cardiac myocytes from control and etomoxir-treated rats
(Figures 5C and 5D).
Basal glucose uptake into cardiac myocytes was similar
between control and etomoxir-treated rats incubated with 100 μM
palmitate (Figure 5E). At 600 μM palmitate, basal glucose
uptake into cardiac myocytes from both rat groups was 5-fold
lower (Figure 5F), which is probably due to LCFA-induced
inhibition of glucose metabolism according to the principles of
the Randle cycle [25]. Oligomycin treatment similarly enhanced
glucose uptake by 3.8-fold into cardiac myocytes from control
and etomoxir-treated rats incubated with 100 μM palmitate
(Figure 5E), and by 17-fold when incubated with 600 μM
palmitate (Figure 5F).
DISCUSSION
The primary purpose of this study was to assess the role of
CPT-I in the control of cardiac LCFA fluxes. In etomoxir-treated
rats, a chronic reduction of cardiac CPT-I activity by 44% did
not adversely alter: (i) cardiac CD36 and FABPpm expression
and sarcolemmal localization; (ii) cardiac sarcolemmal LCFA
transport capacity; and (iii) cardiac triacylglycerol deposition.
The partial CPT-I reduction also did not affect: (iv) LCFA
uptake rates; (v) LCFA oxidation rates; and (vi) glucose uptake
rates into cardiac myocytes both under basal and under acutely
induced maximal metabolic demands in combination with either
physiologically low or high LCFA supply. Collectively, these
results indicate that reducing CPT-I activity does not impair any
aspect of LCFA and glucose metabolism in the heart.
A partial reduction in CPT-I activity is not rate-limiting for cardiac
LCFA utilization
Etomoxir is a commonly used irreversible inhibitor of CPT-I,
which results in blocking the entry of long-chain fatty acyl-
moieties into mitochondria, and a subsequent reduction in the
rate of β-oxidation. Etomoxir is an effective CPT-I inhibitor
in the heart, since its addition in micromolar concentrations to
cardiac myocytes in vitro inhibited LCFA oxidation by >95%
[11]. In the present study in vivo, using a daily dose of
20 mg/kg of body mass, CPT-I activity was partially blocked
by 44%. However, expression of M-CPT-I, the major cardiac
isoform, was increased by 1.7-fold. This compensatory up-
regulation presumably prevented a more dramatic reduction in
total CPT-I activity, with more severe consequences for body
lipid homoeostasis.
CPT-1 has long been considered the key regulatory enzyme
involved in mitochondrial uptake of LCFA [1,6]. However, its
role in the control of the cardiac LCFA fluxes is incompletely
understood [26]. In the theoretical case that CPT-I would be a
major control site of cardiac LCFA fluxes, it would probably exert
a feedback inhibition on the sarcolemmal LCFA uptake process to
prevent an intracellular accumulation of toxic LCFA metabolites.
This feedback inhibition of sarcolemmal LCFA uptake might
include a possible repression of CD36 and FABPpm and/or an
internalization of these LCFA transporters. According to the flux-
control theory [5,27], a ∼40–50% inhibition in CPT-I would
theoretically result in at least a partial inhibition of cellular LCFA
uptake. However, despite marked reductions in CPT-I activity,
there were no adverse effects on the expression and subcellular
localization of LCFA transporters, nor on the sarcolemmal LCFA
transport capacity or cellular LCFA uptake rates under basal and
maximal metabolic demands.
Notwithstanding that CPT-I reduction does not have any
impact on sarcolemmal LCFA transport and transporters, a
more restricted control on mitochondrial β-oxidation would be
expected [1,6]. Again, a ∼50% reduction of CPT-I activity would
be expected to result in a ∼50% reduction of mitochondrial
β-oxidation, according to the flux-control theory of rate-limiting
enzymes [27]. However, chronic reduction of CPT-I by 44 %
was without any effect on LCFA oxidation, even under maximal
substrate supply. Moreover, powerful stimulation of LCFA
oxidation by short-term (15 min) oligomycin-induced AMPK
activation and subsequent ACC inhibition was not affected by
the etomoxir treatment. Hence, the 56% residual CPT-I levels
are sufficient to allow maximal (acute) up-regulation of LCFA
oxidation. These findings by themselves do contra-indicate the
view that CPT-I is rate-limiting in mitochondrial β-oxidation.
Importantly, this conclusion is in agreement with previous more
indirect observations concerning the marked up-regulation of
mitochondrial β-oxidation in hearts from db/db mice in the
absence of changes in CPT-I expression [10], and provides an
explanation for the paradoxical observation that the estimated
intramyocellular malonyl-CoA concentration exceeds the IC50 of
M-CPT-I for malonyl-CoA by >50-fold (see the Introduction
section) [5,8,9].
Furthermore, etomoxir treatment had no effect on the intra-
myocellular triacylglycerol concentration, and therefore the
∼50% CPT-I activity reduction does not result in a compensatory
increase in triacylglycerol esterification of LCFA taken up into
cardiac myocytes. Finally, etomoxir treatment does not affect
glucose uptake, which would have been expected to increase in a
secondary response to a hypothetical reduction of β-oxidation
according to the principles of the Randle cycle [25]. Taken
together, a ∼50% reduction in CPT-I failed to reduce any aspect
of cardiac LCFA utilization, pointing towards a more permissive,
rather than a regulatory, role for CPT-I in mediating cardiac LCFA
fluxes.
Importantly, this conclusion on the lack of flux control exerted
by CPT-I in the heart may be tissue-specific. In other tissues,
CPT-I might still be important in the control of mitochondrial
β-oxidation. An example would be the liver, where L-CPT-I
is the predominant isoform, which is far less sensitive than
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Figure 5 Effect of in vivo etomoxir treatment on substrate utilization into cardiac myocytes
Cardiac myocytes were isolated from contol rats (C) and etomoxir-treated rats (Eto). Cardiac myocytes were then incubated for 15 min in the absence or presence of 30 μM oligomycin (Oli), and
subsequently used for measurement of palmitate uptake (A and B), palmitate oxidation (C and D), and deoxyglucose uptake (E and F) at 100 μM (A, C and E) and 600 μM (B, D and F) externally
added palmitate. Light grey bars represent non-stimulated cardiac myocytes from control rats and etomoxir-treated rats. Corresponding dark bars represent oligomycin-treated cardiac myocytes from
control rats and etomoxir-treated rats. Results are means +− S.E.M. for experiments carried out with cardiac myocyte preparations from six rats in each group. ∗Significantly different from control
(P < 0.05).
M-CPT-I to inhibition by malonyl-CoA [5]. In the present study,
we observed a 56% reduction in hepatic CPT-I activity with the
etomoxir treatment. However, in contrast with the heart, in which
triacylglycerols did not accumulate, the liver exhibited a 2.1-fold
increase in triacylglycerol content, indicating that modulation of
CPT-I activity has an impact on hepatic LCFA metabolism.
Etomoxir-induced cardiac hypertrophy is not caused by changes in
cardiac LCFA utilization
Chronic etomoxir treatment of rats has been frequently used as
a rodent model to study the molecular mechanisms underlying
the development of cardiac hypertrophy. Indeed, in the present
study, etomoxir treatment caused an 11% increase in heart mass.
Etomoxir-induced cardiac hypertrophy was accompanied by an
elevated expression of myosin isoform V1, sarcoplasmic reticulum
Ca2+-ATPase [13,28] and Na+-K+-ATPase [29]. The mechanism
by which etomoxir induces the expression of myosin isoform
V1 and sarcoplasmic reticulum Ca2+-ATPase is incompletely
understood, but is probably connected with inhibition of CPT-I
and the resulting chronic metabolic shift from LCFA oxidation
to glucose utilization [30]. Hence the metabolic switch induced
by CPT-I blockade is considered a key signal for this type for
cardiac remodelling. Therefore transcription factors sensitive
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to changes in LCFA or LCFA metabolites are considered as
likely candidates in the switch in genetic programming [31].
However, the present study, in which etomoxir-induced CPT-I
inhibition did not alter cardiac LCFA utilization, suggests that
the switch in gene expression might not be due to LCFA- (or
LCFA metabolite-) induced transcription factors. Indeed, PPARα
(peroxisome-proliferator-activated receptor α) expression and
PPARα target genes were not increased in chronic etomoxir
treatment of mice [16]. Interestingly, it has been reported that
etomoxir (or its metabolite etomoxiryl-CoA) activates other
transcription factors via LCFA-independent mechanisms. In this
respect, etomoxir-induced down-regulation of peroxisomal acyl-
CoA oxidase appeared to cause oxidative stress and, hence, NF-
κB (nuclear factor κB) activation [16].
Implications for treatment of cardiac metabolic diseases
There is emerging evidence that cardiac diseases are, at least
partially, caused by alterations in cardiac energy substrate
metabolism. For instance, the insulin resistant/Type 2 diabetic
heart shows increased LCFA uptake and oxidation, which is
accompanied by diastolic malfunctioning [32–34]. Therefore,
therapeutic manipulations to reduce the cardiac LCFA flux should
be beneficial for the diseased heart and restore cardiac function
[3,35,36]. Moreover, because heart failure decreases the energy
reserve of the heart and LCFA oxidation is less efficient in
terms of oxygen consumption than glucose oxidation [35,36],
this would provide another reason why reduction of LCFA fluxes
might improve cardiac contractile parameters. The most efficient
target for such therapy is the rate-limiting step in cardiac LCFA
utilization. On the basis of the present results, it appears that CPT-I
does not represent the predominant control site. Instead, there
is growing evidence that cardiac LCFA fluxes are regulated at
the level of the LCFA transport system consisting of FABPpm
and CD36, i.e. via altered distribution of these transporters
between intracellular membrane compartments (endosomes) and
the sarcolemma [3]. Also, other LCFA transporters have been
proposed to function in mammalian tissues, such as members
of the FATP (fatty-acid transport protein) family, caveolin-1
and a putative adipocyte membrane protein pump [37], but the
expression of the first two proteins is restricted to adipocytes
[21,37], and FATPs have been shown not to play a major role
in bulk LCFA uptake into the heart [2,38]. In this light, agents
reducing the flux through FABPpm and CD36, rather than CPT-I
inhibitors, would seem to be the preferable therapeutic agents for
the treatment of cardiac disease.
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